By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cortice Biosciences 

50 W 57th Street, 15th Floor

New York  New York  10019  U.S.A.
Phone: 646-747-9090 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Cortice Biosciences Announces Initial Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 11/14/2014 7:20:19 AM
Cortice Biosciences Announces Results From Studies Evaluating Pipeline Candidates TPI 287 And CRT 001 In Preclinical Models Of Tauopathies And Alzheimer's Disease 11/12/2014 7:31:05 AM
Cortice Biosciences Announces Upcoming Presentations At The 2014 Cell Symposia For Translational Neuroscience And The Annual Meeting Of The Society for Neuroscience 11/5/2014 10:05:58 AM
Cortice Biosciences Announces Upcoming Presentation At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/3/2014 10:27:00 AM
Cortice Biosciences Announces Acquisition Of Exclusive Rights To A Novel Neurological Disease Therapeutic And Development Platform 7/31/2014 10:43:08 AM
Cortice Biosciences Announces Enrollment Of A Phase 1 Clinical Trial Evaluating TPI 287 In Rare Tauopathy Diseases 7/7/2014 8:21:11 AM
Cortice Biosciences Announces Enrollment Of A Phase 2 Trial Evaluating TPI 287 Plus Avastin® For Treatment Of Glioblastoma Previously Treated With Anti-Angiogenic Therapy 3/20/2014 8:53:03 AM
Cortice Biosciences Announces Enrollment Of A Clinical Trial Targeting Tau Dysfunction In Mild-To-Moderate Alzheimer's Disease 1/22/2014 8:57:47 AM
Cortice Biosciences Announces Enrollment Of A Clinical Trial Targeting Tau Dysfunction In Mild-To-Moderate Alzheimer's Disease 1/21/2014 9:07:19 AM
Cortice Biosciences Announces Enrollment Of A Phase 2 Trial Evaluating TPI 287 Plus Avastin® For Treatment Of Recurrent Glioblastoma Naive To Prior Anti-Angiogenic Therapy 1/9/2014 9:35:51 AM
12
//-->